Recent progress in the discovery of inhibitors targeting coronavirus proteases

Virol Sin. 2016 Feb;31(1):24-30. doi: 10.1007/s12250-015-3711-3. Epub 2016 Feb 19.

Abstract

Coronaviruses (CoVs) can cause highly prevalent diseases in humans and animals. The fatal outbreak of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) highlights the threat posed by this unique virus subfamily. However, no specific drugs have been approved to treat CoV-associated diseases to date. The CoV proteases, which play pivotal roles in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, are attractive targets for drug design. This review summarizes the recent advances in biological and structural studies, together with the development of inhibitors targeting CoV proteases, particularly main proteases (M(pro)s), which could help develop effective treatments to prevent CoV infection.

Keywords: coronaviruses; main protease; protease inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Coronavirus / enzymology
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / virology*
  • Drug Discovery
  • Humans
  • Peptide Hydrolases / metabolism*
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology*
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Protease Inhibitors
  • Peptide Hydrolases